Jacob Robert Bledsoe, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma | 4 | 2024 | 1896 | 1.520 |
Why?
|
Plasma Cells | 3 | 2021 | 599 | 1.060 |
Why?
|
Immunoglobulin G | 6 | 2024 | 4560 | 1.030 |
Why?
|
Asbestosis | 2 | 2015 | 81 | 0.950 |
Why?
|
Torque teno virus | 1 | 2024 | 13 | 0.920 |
Why?
|
Carcinoma, Signet Ring Cell | 2 | 2020 | 80 | 0.820 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 249 | 0.800 |
Why?
|
Bone Marrow Diseases | 1 | 2023 | 234 | 0.740 |
Why?
|
Anemia, Aplastic | 1 | 2023 | 231 | 0.740 |
Why?
|
Pulmonary Fibrosis | 2 | 2015 | 505 | 0.720 |
Why?
|
Biliary Tract | 1 | 2021 | 136 | 0.700 |
Why?
|
Frozen Sections | 1 | 2020 | 153 | 0.650 |
Why?
|
Neutropenia | 1 | 2024 | 892 | 0.640 |
Why?
|
Anal Canal | 1 | 2021 | 375 | 0.610 |
Why?
|
Staining and Labeling | 2 | 2021 | 1076 | 0.580 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2017 | 38 | 0.570 |
Why?
|
Myelodysplastic Syndromes | 3 | 2024 | 1399 | 0.570 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2021 | 343 | 0.560 |
Why?
|
Myeloproliferative Disorders | 1 | 2023 | 616 | 0.550 |
Why?
|
Anus Neoplasms | 1 | 2021 | 336 | 0.550 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1608 | 0.510 |
Why?
|
Immunophenotyping | 2 | 2021 | 1864 | 0.500 |
Why?
|
Immune System Diseases | 1 | 2017 | 253 | 0.490 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4049 | 0.490 |
Why?
|
Interferon Regulatory Factors | 1 | 2016 | 271 | 0.480 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1639 | 0.470 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 561 | 0.460 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2015 | 304 | 0.440 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1433 | 0.440 |
Why?
|
Mediastinal Neoplasms | 1 | 2016 | 403 | 0.430 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2058 | 0.420 |
Why?
|
Pancreatitis, Chronic | 1 | 2015 | 282 | 0.400 |
Why?
|
Immunohistochemistry | 5 | 2023 | 11063 | 0.360 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2952 | 0.350 |
Why?
|
Carcinoma | 1 | 2021 | 2326 | 0.330 |
Why?
|
Bile Duct Neoplasms | 1 | 2015 | 614 | 0.330 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1481 | 0.330 |
Why?
|
Diagnostic Errors | 3 | 2021 | 1278 | 0.320 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12069 | 0.310 |
Why?
|
Diagnosis, Differential | 7 | 2024 | 12986 | 0.300 |
Why?
|
Lymph Nodes | 4 | 2024 | 3468 | 0.300 |
Why?
|
Smoking | 2 | 2015 | 9081 | 0.290 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1131 | 0.280 |
Why?
|
Lung | 2 | 2015 | 10076 | 0.260 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2255 | 0.260 |
Why?
|
Mutation | 7 | 2024 | 30211 | 0.250 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 1559 | 0.230 |
Why?
|
Histiocytic Sarcoma | 1 | 2024 | 40 | 0.230 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2015 | 1759 | 0.220 |
Why?
|
Lymphocyte Transfusion | 1 | 2024 | 232 | 0.210 |
Why?
|
Adrenoleukodystrophy | 1 | 2024 | 144 | 0.200 |
Why?
|
Primary Myelofibrosis | 1 | 2024 | 208 | 0.200 |
Why?
|
Humans | 41 | 2024 | 767040 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20741 | 0.190 |
Why?
|
Adenoma | 1 | 2012 | 2155 | 0.190 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 230 | 0.190 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6360 | 0.190 |
Why?
|
Lentivirus | 1 | 2024 | 518 | 0.190 |
Why?
|
Hepatic Stellate Cells | 1 | 2022 | 117 | 0.190 |
Why?
|
Middle Aged | 18 | 2024 | 223233 | 0.190 |
Why?
|
Thymoma | 1 | 2023 | 186 | 0.190 |
Why?
|
Lipids | 1 | 2012 | 3322 | 0.190 |
Why?
|
Synaptophysin | 1 | 2021 | 138 | 0.180 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 4114 | 0.180 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2020 | 58 | 0.180 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.180 |
Why?
|
Thymus Neoplasms | 1 | 2023 | 272 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2015 | 13491 | 0.170 |
Why?
|
Aged | 15 | 2021 | 171319 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2024 | 3667 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 384 | 0.170 |
Why?
|
Fanconi Anemia | 1 | 2022 | 327 | 0.170 |
Why?
|
Receptors, CXCR4 | 1 | 2024 | 729 | 0.160 |
Why?
|
Ampulla of Vater | 1 | 2020 | 150 | 0.160 |
Why?
|
Germ Cells | 1 | 2023 | 644 | 0.160 |
Why?
|
Human papillomavirus 16 | 1 | 2021 | 268 | 0.160 |
Why?
|
Pelvic Neoplasms | 1 | 2021 | 249 | 0.160 |
Why?
|
Kidney Pelvis | 1 | 2020 | 191 | 0.160 |
Why?
|
Aged, 80 and over | 8 | 2021 | 59548 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2355 | 0.160 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15424 | 0.150 |
Why?
|
Male | 22 | 2024 | 364203 | 0.150 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 204 | 0.150 |
Why?
|
Telepathology | 1 | 2018 | 77 | 0.150 |
Why?
|
Colorectal Neoplasms | 2 | 2016 | 6966 | 0.150 |
Why?
|
Female | 21 | 2024 | 396660 | 0.150 |
Why?
|
Dacryocystitis | 1 | 2018 | 68 | 0.140 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11217 | 0.140 |
Why?
|
Pancreatic Neoplasms | 1 | 2015 | 5446 | 0.140 |
Why?
|
Liver Transplantation | 2 | 2020 | 2416 | 0.140 |
Why?
|
Adult | 13 | 2024 | 223317 | 0.140 |
Why?
|
DNA Methylation | 2 | 2024 | 4426 | 0.140 |
Why?
|
Barrett Esophagus | 1 | 2020 | 494 | 0.140 |
Why?
|
Survival Analysis | 2 | 2021 | 10092 | 0.130 |
Why?
|
Donor Selection | 1 | 2018 | 242 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 686 | 0.130 |
Why?
|
Cholangitis, Sclerosing | 1 | 2018 | 179 | 0.130 |
Why?
|
beta Catenin | 1 | 2021 | 1048 | 0.130 |
Why?
|
Gene Rearrangement | 1 | 2020 | 1141 | 0.120 |
Why?
|
Azacitidine | 1 | 2017 | 336 | 0.120 |
Why?
|
Biopsy | 5 | 2020 | 6777 | 0.120 |
Why?
|
Actins | 1 | 2022 | 2059 | 0.120 |
Why?
|
Genetic Vectors | 1 | 2024 | 3402 | 0.120 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2017 | 781 | 0.120 |
Why?
|
Metformin | 1 | 2022 | 908 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 22350 | 0.110 |
Why?
|
Fatty Liver | 1 | 2020 | 811 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4892 | 0.110 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 1244 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2887 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1907 | 0.100 |
Why?
|
Microsatellite Instability | 1 | 2016 | 726 | 0.100 |
Why?
|
Vacuoles | 1 | 2012 | 224 | 0.100 |
Why?
|
Liver | 2 | 2018 | 7578 | 0.090 |
Why?
|
Pancreatitis | 1 | 2018 | 1087 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20169 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2015 | 399 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1661 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1105 | 0.090 |
Why?
|
Young Adult | 5 | 2022 | 59980 | 0.080 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2016 | 1801 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2021 | 81659 | 0.080 |
Why?
|
Tissue Donors | 1 | 2018 | 2387 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2016 | 1383 | 0.080 |
Why?
|
Observer Variation | 1 | 2014 | 2616 | 0.080 |
Why?
|
Prognosis | 2 | 2021 | 29963 | 0.070 |
Why?
|
Lung Diseases | 1 | 2018 | 1942 | 0.070 |
Why?
|
Amyloidosis | 1 | 2015 | 876 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3370 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2099 | 0.070 |
Why?
|
Liver Diseases | 1 | 2015 | 1304 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 912 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39317 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6844 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2017 | 2535 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 3626 | 0.060 |
Why?
|
Adolescent | 3 | 2024 | 89046 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 367 | 0.050 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2023 | 430 | 0.050 |
Why?
|
Heat-Shock Response | 1 | 2022 | 179 | 0.050 |
Why?
|
Hematoxylin | 1 | 2020 | 61 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 70 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2020 | 65295 | 0.050 |
Why?
|
Blast Crisis | 1 | 2021 | 102 | 0.050 |
Why?
|
Risk Assessment | 2 | 2020 | 24299 | 0.040 |
Why?
|
Esophagoscopy | 1 | 2020 | 398 | 0.040 |
Why?
|
Heat-Shock Proteins | 1 | 2022 | 792 | 0.040 |
Why?
|
Remission Induction | 1 | 2024 | 2408 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 565 | 0.040 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2023 | 1391 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15925 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1621 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 928 | 0.030 |
Why?
|
Living Donors | 1 | 2020 | 647 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4838 | 0.030 |
Why?
|
Microscopy | 1 | 2020 | 903 | 0.030 |
Why?
|
Child | 4 | 2024 | 80771 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2024 | 2744 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2800 | 0.030 |
Why?
|
Abdomen | 1 | 2020 | 1138 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13646 | 0.030 |
Why?
|
Laser Therapy | 1 | 2020 | 1108 | 0.030 |
Why?
|
Tumor Escape | 1 | 2016 | 371 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8628 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1959 | 0.020 |
Why?
|
Risk Factors | 2 | 2016 | 74886 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2843 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1903 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3431 | 0.020 |
Why?
|
Genotype | 1 | 2024 | 13035 | 0.020 |
Why?
|
Graft Survival | 1 | 2020 | 3896 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5311 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 1642 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 2040 | 0.020 |
Why?
|
Weight Loss | 1 | 2020 | 2716 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12793 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7446 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3883 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2022 | 14476 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16718 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5716 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10254 | 0.020 |
Why?
|
Mice | 2 | 2023 | 81912 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12823 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5796 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6513 | 0.020 |
Why?
|
Odds Ratio | 1 | 2016 | 9660 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3828 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3944 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12536 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13284 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168965 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14672 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17097 | 0.010 |
Why?
|